Lonza Group AG | Finanzwire

BRIEF

published on 09/24/2024 at 14:05, 1 month 28 days ago

Lonza and Vertex Sign Long-Term Supply Agreement for CASGEVY®

Lonza Cell Therapy Vertex CASGEVY® CRISPR/Cas9
PRESS RELEASE

published on 09/24/2024 at 14:00, 1 month 28 days ago

Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel)
Lonza and Vertex sign a long-term commercial supply agreement for CASGEVY® cell therapy based on CRISPR/Cas9 gene-editing technology. Lonza to manufacture at Geleen, NL facility approved by FDA, EMA, and MHRA

Lonza Cell Therapy Vertex CASGEVY® CRISPR/Cas9
BRIEF

published on 08/28/2024 at 18:36, 2 months 25 days ago

Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds

Lonza EUR 1.2 Billion Corporate Financing Dual-Tranche Bonds Luxembourg Listing
PRESS RELEASE

published on 08/28/2024 at 18:31, 2 months 25 days ago

Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds
Lonza Group AG's wholly-owned Lonza Finance International NV prices dual-tranche EUR 1.2 billion straight bonds with 3.25% and 3.50% coupons for six and ten years respectively. Bonds to be listed on Luxembourg Stock Exchange for general corporate purposes

Lonza Group AG Listing EUR 1.2 Billion Luxembourg Stock Exchange Straight Bonds
BRIEF

published on 07/25/2024 at 07:05, 3 months 29 days ago

Lonza Nominates Juan Andres and Eric Drapé as Independent Board Members

Pharmaceutical Industry Lonza Board Nominations Juan Andres Eric Drapé
PRESS RELEASE

published on 07/25/2024 at 07:00, 3 months 29 days ago

Lonza Nominates Juan Andres and Eric Drapé as Independent Board Members
Lonza nominates Juan Andres and Eric Drapé as independent board members to enhance governance and expertise. The nominees bring decades of leadership in the pharmaceutical industry

Pharmaceutical Industry Lonza Juan Andres Eric Drapé Independent Board Members
BRIEF

published on 07/25/2024 at 07:00, 3 months 29 days ago

Lonza Group H1 2024 Performance on Track: Sales Increase 1.8% CER, CORE EBITDA Margin at 29.2%

Financial Performance Sales Growth Lonza Group H1 2024 Results CORE EBITDA
PRESS RELEASE

published on 07/25/2024 at 06:55, 3 months 29 days ago

Lonza Group H1 2024 Performance Well On Track to Deliver Full-Year Outlook: Sales Up 1.8% CER and 29.2% CORE EBITDA Margin
Lonza Group H1 2024 performance on track: 1.8% sales increase, 29.2% CORE EBITDA margin. Full-Year Outlook confirmed

CORE EBITDA Margin Sales Increase Full-year Outlook Lonza Group H1 2024 Performance
BRIEF

published on 07/01/2024 at 07:05, 4 months 22 days ago

Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand

Appointment Lonza CEO Wolfgang Wienand
PRESS RELEASE

published on 07/01/2024 at 07:00, 4 months 22 days ago

Lonza Welcomes New Group Chief Executive Officer Wolfgang Wienand
Lonza Group welcomes Wolfgang Wienand as new CEO, succeeding Albert M. Baehny. Smooth leadership transition planned before Albert's retirement this summer

Leadership Transition CEO Retirement Wolfgang Wienand Lonza Group

Published on 11/22/2024 at 23:55, 9 hours 11 minutes ago

Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 9 hours 36 minutes ago

Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 10 hours 1 minute ago

Kidoz Inc. Announces Results of 2024 AGM
Published on 11/22/2024 at 23:05, 10 hours 1 minute ago

Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 10 hours 36 minutes ago

Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 14 hours 51 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 15 hours 6 minutes ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 15 hours 12 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 16 hours 10 minutes ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 17 hours 6 minutes ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 14:35, 18 hours 30 minutes ago

Thales Press release
Published on 11/21/2024 at 06:58, 2 days 2 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 2 days 13 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 2 days 15 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 2 days 15 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024

View all LES ECHOS COMFI WIRE

News